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Evidence for Defects in the Trafficking and Translocation of GLUT4 Glucose
Transporters in Skeletal Muscle as a Cause of Human Insulin Resistance
W. Timothy Garvey,* Lidia Maianu,* Ju-Hong Zhu,* Ginger Brechtel-Hook,‡ Penny Wallace,* and Alain D. Baron‡
*Department of Medicine, Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston,
South Carolina 29425; and ‡Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Affairs
Medical Center, Indianapolis, Indiana 46202

Abstract
Insulin resistance is instrumental in the pathogenesis of
type 2 diabetes mellitus and the Insulin Resistance Syndrome. While insulin resistance involves decreased glucose
transport activity in skeletal muscle, its molecular basis is
unknown. Since muscle GLUT4 glucose transporter levels
are normal in type 2 diabetes, we have tested the hypothesis
that insulin resistance is due to impaired translocation of intracellular GLUT4 to sarcolemma. Both insulin-sensitive
and insulin-resistant nondiabetic subgroups were studied, in
addition to type 2 diabetic patients. Biopsies were obtained
from basal and insulin-stimulated muscle, and membranes
were subfractionated on discontinuous sucrose density gradients to equilibrium or under nonequilibrium conditions
after a shortened centrifugation time. In equilibrium fractions from basal muscle, GLUT4 was decreased by 25–29%
in both 25 and 28% sucrose density fractions and increased
twofold in both the 32% sucrose fraction and bottom pellet
in diabetics compared with insulin-sensitive controls, without any differences in membrane markers (phospholemman,
phosphalamban, dihydropyridine-binding complex a-1 subunit). Thus, insulin resistance was associated with redistribution of GLUT4 to denser membrane vesicles. No effects of
insulin stimulation on GLUT4 localization were observed.
In non-equilibrium fractions, insulin led to small GLUT4
decrements in the 25 and 28% sucrose fractions and increased GLUT4 in the 32% sucrose fraction by 2.8-fold over
basal in insulin-sensitive but only by 1.5-fold in both insulinresistant and diabetic subgroups. The GLUT4 increments in
the 32% sucrose fraction were correlated with maximal in
vivo glucose disposal rates (r 5 10.51, P 5 0.026), and,
therefore, represented GLUT4 recruitment to sarcolemma or
a quantitative marker for this process. Similar to GLUT4,
the insulin-regulated aminopeptidase (vp165) was redistributed to a dense membrane compartment and did not translocate in response to insulin in insulin-resistant subgroups.
In conclusion, insulin alters the subcellular localization
of GLUT4 vesicles in human muscle, and this effect is im-
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paired equally in insulin-resistant subjects with and without
diabetes. This translocation defect is associated with abnormal accumulation of GLUT4 in a dense membrane compartment demonstrable in basal muscle. We have previously
observed a similar pattern of defects causing insulin resistance in human adipocytes. Based on these data, we propose that human insulin resistance involves a defect in
GLUT4 traffic and targeting leading to accumulation in a
dense membrane compartment from which insulin is unable
to recruit GLUT4 to the cell surface. (J. Clin. Invest. 1998.
101:2377–2386.) Key words: insulin resistance • type 2 diabetes
mellitus • insulin-regulated aminopeptidase (vp165) • vesicle
trafficking • GLUT4

Introduction
Insulin resistance is key to the pathogenesis of type 2 diabetes
mellitus and is also a risk factor associated with hypertension
and cardiovascular disease (1, 2). The clinical manifestations of
insulin resistance, glucose intolerance and hyperinsulinemia,
are the consequence of the inability of insulin to stimulate glucose uptake in such insulin target tissues as muscle and fat. The
underlying defect must be expressed in skeletal muscle, which
accounts for 70–80% of insulin-stimulated glucose uptake in
vivo (3), and current data point to reduced glucose transport
activity, the rate-limiting step for glucose uptake (4). Hyperinsulinemic glucose clamp studies and limb balance studies have
consistently demonstrated impaired stimulation of muscle glucose uptake in type 2 diabetes (1); however, these techniques
do not discriminate whether this is because of a reduction in
transport activity or intracellular glucose metabolism. In fact,
Bonnadonna et al., using a novel isotope tracer and limb balance approach (5), and Kelley et al. (6), analyzing rate constants for [18F]2-deoxyglucose uptake during positron emission
scanning, have provided evidence for separate defects in both
transport and glucose phosphorylation in type 2 diabetes.
However, under conditions of stimulated glucose flux, investigators have found that free glucose and glucose-6-phosphate
do not accumulate in skeletal muscle (4, 7–9) and that metabolism within intracellular pathways can be normalized (10–12).
These latter data indicate that transport system defects likely
predominate in mediating insulin resistance. Most compelling
are ex vivo studies that show that the ability of insulin to stimulate glucose transport is markedly impaired in muscle strips
and adipocytes removed from insulin resistant patients (13–16).
The molecular basis of insulin resistance remains unclear.
Insulin stimulates glucose transport via translocation of GLUT4
glucose transporter proteins from an intracellular depot to the
cell surface. In fat cells, GLUT4 expression is markedly reduced in type 2 diabetes and obesity (15). While other defects
may exist in insulin action pathways, GLUT4 depletion appears to be the major cause of insulin resistance in fat because
of the profound degree to GLUT4 loss and its central role in
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transport stimulation. However, in skeletal muscle, GLUT4
levels were found to be normal in multiple insulin-resistant disease states, including obesity, type 2 diabetes, impaired glucose tolerance, and gestational diabetes (17, 18). This has
given rise to the inference that defects in GLUT4 translocation
cause insulin resistance in muscle (17, 18), and supportive data
are available (6, 19). Such an abnormality could arise from defects in insulin signal transduction or defects in GLUT4 traffic
and targeting that lie intrinsic to the glucose transport effector
system. Investigators have demonstrated that insulin receptor
tyrosine kinase activity, together with downstream signaling
events (for example, insulin receptor substrate 1 phosphorylation, phosphatidylinositol-3 kinase activation), are reduced in
skeletal muscle (20). Thus, one potential cause of human
insulin resistance is a defect in insulin signaling that impairs
GLUT4 translocation in muscle.
The presence of signaling defects does not exclude the possibility that critical defects could lie within the glucose transport apparatus. It has become clear that intracellular sequestration and translocation of GLUT4 are regulated by motifs
intrinsic to the GLUT4 molecule (21) together with a host of
proteins directing vesicle traffic (22–25). The complexity of
this system provides multiple potential loci for defects that
could interrupt insulin-mediated GLUT4 translocation, and
this has increased scientific interest in this area. In adipocytes
from women with gestational diabetes, we have shown that impaired GLUT4 translocation was associated with redistribution of GLUT4 to dense membrane vesicles in basal cells suggestive of a defect in transporter trafficking or targeting (16).
However, to date, there is no evidence in muscle that defects in
GLUT4 trafficking operate as a cause of insulin resistance. In
this study, we used a biochemical approach involving subcellular membrane subfractionation of muscle, and, for the first
time, implicate defects in GLUT4 traffic and targeting as a
cause of impaired GLUT4 translocation and insulin resistance
in subjects with and without type 2 diabetes.

tionation (see below). The nondiabetic subjects in protocol 2 were
categorized as insulin sensitive or insulin resistant based on maximally insulin-stimulated glucose uptake rates . or , 15 mg/kg/min,
respectively, during hyperinsulinemic euglycemic clamp studies. All
type 2 diabetic patients were being treated with sulfonylurea oral hypoglycemic agents, and were withdrawn from therapy for at least 3 wk
and followed on an outpatient basis. All subjects were chemically euthyroid and without renal, hepatic, or cardiac disease. No subject was
ingesting pharmacological agents known to affect carbohydrate homeostasis.

In vivo studies

Subjects

After we obtained informed consent, we studied nondiabetic and untreated diabetic subjects on a metabolic ward where they remained
active. The subjects were allowed to equilibrate on a weight-maintenance diet (28–32 kcal/kg/d), consisting of 50% carbohydrate, 35%
fat, and 15% protein. We performed standard 75-g oral glucose tolerance tests (26). We assessed peripheral insulin sensitivity (Table I) using the hyperinsulinemic euglycemic glucose clamp technique as previously described (27, 28). During continuous insulin infusion (400
mU/m2/min), the overall glucose disposal rate was calculated on the
basis of the glucose infusion rate corrected for changes in glucose
pool size, assuming a distribution volume of 19% body weight and
pool fraction of 0.65. Hepatic glucose output has been shown to be
completely suppressed at the high maximally effective insulin concentrations achieved during the clamp (27). During the steady-state period, the serum glucose was maintained at 90 mg/dl with a coefficient
of variation , 4% by monitoring serum glucose levels at 5-min intervals and adjusting the infusion rate of a 20% dextrose solution. Glucose uptake rates were normalized for lean body mass (excluding
bone mass) determine by whole-body, dual-energy x-ray absorptiometry scanning.
We performed percutaneous needle biopsies of the vastus lateralis as previously described (18). In each subject, one biopsy was performed under basal conditions before initiating the clamp study and a
second was performed in the contralateral leg after 3 h of steady-state
hyperinsulinemia. In some subjects, the second biopsy was performed
30 min after initiating the insulin infusion. To perform the biopsy, a
side-cutting needle (Poppler and Sons, New Hyde Park, NY) was inserted through a small incision in locally anesthetized skin (2%
lidocaine), z 10–15 cm above the patella on the anterolateral thigh,
and z 400 mg muscle tissue was retrieved. This tissue was then blotted on sterile cloth, placed immediately into liquid N2, and stored at
2808C. The time between the actual biopsy and snap-freezing of the
tissue in liquid N2 was 5–10 s.

Table I shows clinical characteristics of the study groups. We studied
subjects with normal oral glucose tolerance and patients with type 2
diabetes mellitus (26). Muscle biopsies were processed using two protocols (protocols 1 and 2) based on differences in membrane subfrac-

Frozen vastus lateralis muscle tissue (z 400 mg) was placed in 5 vol of
buffer (pH 7.6) at 48C containing 10 mM Tris-HCl, 0.25 M sucrose,

Methods

Muscle membrane subfractionation

Table I. Clinical Characteristics
Subgroup

Protocol 1
Controls
Type 2 diabetes
Protocol 2
Insulin-sensitive
Insulin-resistant
Type 2 diabetes

Number/Gender

Age

Body mass index

Fasting glucose

Fasting insulin

Glucose uptake*

years

kg/m2

mM

pM

mg/kg/min

1F/4M
2F/2M

4162
4462

2261
3864

5.160.2
13.061.0

29612
169653

16.261.1
7.460.5

2F/8M
2F/8M
3F/4M

3562
3463
4361

2662
2662
3564

4.960.1
5.060.2
12.161.5

2467
44616
118631

18.162.0
12.161.6
9.261.1

*Glucose uptake represents maximally insulin-stimulated rates of whole body glucose uptake assessed during hyperinsulinemic euglycemic clamps
and normalized per kg of lean body mass. In protocol 2, nondiabetic subjects were designated as insulin-sensitive or insulin-resistant based on glucose
uptake . of , 15 mg/kg/min, which was the median value.
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and protease inhibitors including 5 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mg/ml pepstatin, and 400 mmol/liter fluoride. The tissue was homogenized first using a Polytron (Brinkmann, Westbury, NY) for five
5-s bursts at a setting of 5 and then with 10 up-and-down strokes of a
motor-driven Teflon pestle in a glass homogenization tube (Thomas
Scientific, Swedesboro, NJ). The homogenate was centrifuged at
1,000 3 g at 48C for 10 min, and the supernatant was saved. The resulting pellet was resuspended in the buffer, rehomogenized with the
glass homogenization tube and Teflon pestle as described above, and
recentrifuged at 1,000 3 g at 48C for 10 min. The resulting supernatant was combined with the first supernatant and together constituted
postnuclear muscle homogenate. The postnuclear homogenate was
then processed using either of two protocols for membrane subfractionation.
Protocol 1 (equilibrium sucrose density gradient centrifugation).
In each subject, postnuclear homogenates from both basal and maximally insulin-stimulated muscle were centrifuged at 9,000 3 g for 10 min,
and the resulting supernatants were then centrifuged at 190,000 3 g
for 60 min. The pellet from each 190,000-3-g centrifugation (crude
membranes) was resuspended in buffer and applied to a discontinuous sucrose density gradient containing 25, 28, and 32% sucrose solutions, respectively. The gradient was centrifuged in a swinging-bucket
rotor at 150,000 3 g for 16 h to achieve equilibrium separation of
membrane subfractions. Membranes were collected at each sucrose
gradient interface, washed by dilution in buffer, and then centrifuged
at 190,000 3 g for 90 min. The resulting pellets (membrane subfractions) were resuspended in buffer and utilized for immunoblot analyses. All steps were conducted at 48C. This method is a modification of
that previously used to demonstrate insulin-mediated translocation of
glucose transporters in rat muscle (29).
Protocol 2 (nonequilibrium sucrose density gradient centrifugation). The postnuclear homogenates from basal and insulin-stimulated muscle were immediately applied to discontinuous density gradients containing 25, 28, and 32% sucrose solutions, respectively.
Each gradient was centrifuged in a swinging-bucket rotor at 150,000 3
g for 3.5 h; this shorter time interval was not sufficient to achieve
equilibrium separation of sucrose density gradient subfractions. The
sucrose solutions were then separated, diluted in buffer, and centrifuged at 190,000 3 g for 90 min. The resulting pellets (membrane subfractions) were resuspended in buffer and utilized for immunoblot
analyses. All steps were conducted at 48C.

Immunoblot analyses
For immunoblot analyses, 50-mg membrane proteins were solubilized
in Laemmli sample buffer (30) and resolved by SDS-PAGE on 1.5mm slab gels containing 7.5–10% polyacrylamide. The proteins were
then electrophoretically transferred to nitrocellulose filters (31). For
immunological detection of GLUT4, nitrocellulose filters were incubated with affinity-purified rabbit antiserum (1:100 dilution) specific
for the COOH-terminal segment (44 amino acids) of the GLUT4
transporter cloned from rat skeletal muscle, as previously described
(18). Three membrane marker enzymes were also analyzed by immunoblot in the same membrane fractions. Phospholamban is exclusively localized to sarcoplasmic reticulum, and was measured using
affinity-purified rabbit antibodies against the canine protein at 1:5,000
dilution (32). Phospholemman was studied as a marker for sarcolemma since it is a chloride channel densely distributed throughout
cell surface membranes in cardiac muscle (33, 34). Anti–phospholemman antibodies were raised in rabbits against a COOH-terminal peptide (residues 58–72), affinity purified, and used at 1:5,000 dilution
(34). The a-1 subunit of the dihydropyridine-binding complex
(DHP)1 was quantified as a t-tubule membrane marker using an mAb
(Novus Molecular, Inc., San Diego, CA) at 1:1,000 dilution (35). In

1. Abbreviations used in this paper: DHP, dihydropyridine-binding
complex; IRAP, insulin-regulated aminopeptidase.

addition, the insulin-regulated aminopeptidase (IRAP) or vp165 (36)
was assayed using polyclonal antibodies raised in rabbits against an
NH2-terminal peptide (5 mg/ml dilution), kindly supplied by Dr. S.
Keller (Dartmouth College). IRAP is a vesicle protein known to be a
constituent of GLUT4-containing vesicles (36, 37). Immunoreactivity
for GLUT4, phospholamban, and phospholemman was identified
using [125I]protein A, while the immunoreactivity for DHP and
IRAP was identified by an enhanced chemiluminescence system
(ECL; Amersham Corp., Arlington Heights, IL). Cross-reacting proteins were quantified by autoradiography and scanning densitometry
(Molecular Dynamics, Sunnyvale, CA). Parallel experiments were
performed to show that each signal in individual subjects was in the
linear range of correlation between signal density and amount of protein loaded on gels. A quantitative comparison among the different
gels was made possible by including five internal standard lanes on
each gel; these lanes contained 50-mg membrane samples from two
human muscle biopsies and 12.5, 50, and 100 mg of crude rat muscle
membrane proteins.

Other assays and statistics
Plasma glucose was measured by the glucose oxidase method with a
glucose analyzer (YSI 2300; Yellow Springs Instruments, Yellow
Springs, OH). Serum insulin levels were measured using a microparticle enzyme immunoassay kit (Abbott Diagnostics, Chicago, IL). Protein was measured by the Coomassie brilliant blue method described
by Bradford (38) with crystalline BSA as the standard. Data are
means6SE. Statistical significance was determined using ANOVA
and Student’s t test to assess post hoc for group-by-group differences.

Results
Protocol 1: Equilibrium-density gradient separation of muscle
membrane subfractions. To examine whether glucose transport system defects contribute to insulin resistance in type 2 diabetes, we initially studied five lean control subjects and four
untreated diabetic patients. As shown in Table I (protocol 1),
the mean age in the control and diabetic subgroups was similar; however, the diabetic patients were obese and exhibited
fasting hyperglycemia and hyperinsulinemia. Maximally insulin-stimulated glucose uptake rates assessed using the euglycemic clamp technique were reduced by 54% in the diabetic
patients compared with insulin-sensitive control subjects (P ,
0.01).
In each subject, vastus lateralis biopsies were obtained under basal conditions and at steady-state serum insulin concentrations that maximally stimulate the glucose transport system.
Muscle membranes were subfractionated on sucrose density
gradients centrifuged overnight to obtain equilibrium separation of subfractions. Fig. 1 shows membrane distribution of
GLUT4 in muscle obtained under basal conditions. In type 2
diabetes, the relative amounts of GLUT4 were decreased by
30% in the 25% sucrose density fraction and by 29% in the
28% fraction (P 5 NS). These decrements corresponded with
a 2.0-fold GLUT4 increment in both the 32% fraction (P ,
0.05) and in the bottom pellet (P , 0.05) compared with controls. Thus, in basal muscle, a greater proportion of GLUT4
was localized in denser membrane fractions in type 2 diabetes.
The total tissue content of GLUT4, determined by immunoblot analysis of total membrane fractions (for example, postnuclear homogenate), was similar in the diabetic and nondiabetic control subgroups (P 5 NS; data not shown) as
previously reported (17, 18).
The observation that GLUT4 was abnormally localized to
denser membrane vesicles in diabetes could be explained by
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Figure 1. Distribution of GLUT4: equilibrium separation of sucrose density membrane subfractions from basal skeletal muscle. Skeletal muscle biopsies were obtained
from insulin-sensitive nondiabetic controls
(closed bars) and from type 2 diabetic
(DM) patients (open bars) under basal conditions. Muscle was homogenized and subfractionated on discontinuous sucrose gradients until equilibrium separation was
achieved. Membrane proteins from each
subfraction (50 mg) were resolved by SDSPAGE, and reacted with GLUT4 antibodies followed by [125I]protein A. Relative
amounts of GLUT4 were quantified by autoradiography and densitometry, and data
represent mean6SE of subgroups delineated in Table I (protocol 1). *P , 0.05 for
DM versus controls.

generalized effects on protein recovery or to nonspecific
changes in membrane composition. To address these possibilities, we measured total protein in the postnuclear homogenate
and each of the membrane fractions, together with phospholemman, a marker for sarcolemma (33, 34), and phospholamban, a marker for sarcoplasmic reticulum (32). Table II delineates data showing recovery of protein and membrane
markers. In comparing control and diabetic subgroups, there
were no statistically significant differences in the recovery of
total protein, phospholemman, or phospholamban in any of
the subfractions (P 5 NS). Thus, major changes in protein recovery or in the subfractionation of sarcolemmal and intracel-

Table II. Protocol 1: Percent Recovery of Protein and
Membrane Markers in Muscle Membrane Subfractions
Sucrose gradient fraction
25%

Protein recovery
Controls
Type 2 diabetes
Phospholemman recovery*
Controls
Type 2 diabetes
Phospholamban recovery*
Controls
Type 2 diabetes

8.261.5
9.062.4

28%

3.560.6
3.060.9

32%

Pellet

2.960.9 20.462.3
3.260.7 19.162.1

27.164.0 17.865.9 12.964.1
30.065.6 13.863.0 14.865.8

7.261.6
6.261.8

17.462.4 10.562.7 11.464.2 10.664.3
16.162.3 10.763.6 14.164.1 7.361.6

*Data represent percent recovery in the membrane fractions of the total
present in post-nuclear homogenates. Density gradient subfractions
were retrieved after equilibrium separation of membranes (see protocol
1). Muscle biopsies were obtained under basal conditions.
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lular membranes could not explain differences in the distribution of GLUT4 in basal muscle.
Muscle biopsies were also obtained in the presence of maximal steady-state serum insulin concentrations and processed
as described for protocol 1. In both controls and diabetes, insulin did not affect the amount of GLUT4 in any of the sucrose
gradient membrane fractions (P 5 NS; data not shown) when
compared with basal data (see Fig. 1). Recoveries of protein,
phospholemman, and phospholamban were not affected by insulin stimulation (P 5 NS; data not shown). In these subjects
(Table I, protocol 1), the second biopsy was performed after
3 h of insulin stimulation during the clamp study. In two additional controls, the second biopsy was obtained 30 min after
initiating the insulin infusion, and again, no effect of insulin
was observed in these membrane subfractions (data not
shown). Thus, insulin-mediated GLUT4 translocation could
not be detected in membrane subfractions obtained from sucrose density gradient fractions at equilibrium following prolonged centrifugation.
Protocol 2: Non–equilibrium-density gradient separation of
muscle membrane subfractions. In another series of experiments, we prepared sucrose density membrane fractions under
non-equilibrium conditions (for example, after a shortened
centrifugation period). Muscle biopsies were obtained from a
greater number of subjects with normal glucose tolerance to
assess glucose transport system defects occurring in the absence of diabetes. These subjects were designated as insulin
sensitive or insulin resistant based on maximally insulin-stimulated glucose uptake rates . or , the median value of 15 mg/
kg/min. As shown in Table I, these two nondiabetic subgroups
were well matched for mean age and body mass index; however, insulin-sensitive subjects were found to have mean maximal glucose uptake rate 50% higher than that observed in the
insulin-resistant subgroup (P , 0.01). Seven type 2 diabetic pa-

Figure 2. Immunoblot of
GLUT4 glucose transporters in
muscle membranes: effects of insulin in non-equilibrium sucrose
density membrane subfractions.
Muscle biopsies were obtained
under basal and insulin-stimulated conditions from an insulinsensitive individual. Muscle was
homogenized and subfractionated on discontinuous sucrose
gradients under non-equilibrium conditions with a shortened
centrifugation time. Membrane
proteins (50 mg) from each
subfraction were resolved by
SDS-PAGE, and reacted with
GLUT4 antibodies followed by
[125I]protein A. The figure represents an autoradiograph. The location of molecular weight
markers is shown on the right.

tients were also studied with higher mean age and body mass
index; they were uniformly insulin resistant.
As before, muscle biopsies were obtained under basal and
hyperinsulinemia conditions, however, the major change from
protocol 1 was that sucrose density gradients were centrifuged
for only 3.5 h and subfractions retrieved before equilibrium
separation. Relative amounts of GLUT4 were assessed in each
membrane subfraction, and an immunoblot from an insulinsensitive subject is shown in Fig. 2. Fig. 3 shows mean GLUT4
amounts detected in the 25 and 32% sucrose gradient fractions, respectively, in all subjects. Insulin infusion produced
small (12–13%) GLUT4 decrements in the 25% sucrose fraction that were not statistically significant (all subgroups P 5
NS). In the 32% sucrose fraction, insulin increased GLUT4,
however, the response was notably different among the subgroups. In the insulin-sensitive subgroup, insulin led to a twofold increase in mean GLUT4 levels in the 32% sucrose fraction (P , 0.01). In both insulin-resistant and type 2 diabetic
subjects, the amounts of GLUT4 in the 32% fraction from in-

sulin-stimulated muscle were not significantly different from
basal GLUT4 levels (P 5 NS). GLUT4 data (not shown) in
the 28% fraction paralleled results observed in the 25% fraction (mean basal and insulin-stimulated values were 10.560.9
and 10.160.8 U/mg membrane protein in insulin-sensitive subjects, 10.361.7 and 8.861.8 in insulin resistant, and 6.661.2
and 6.961.1 in type 2 diabetic subgroups), whereas data in the
bottom pellet were analogous to those in the 32% fraction
(mean basal and insulin-stimulated values were 1.560.5 and
3.160.8 in insulin sensitive, 2.260.5 and 2.460.6 in insulinresistant patients, and 4.060.9 and 4.061.1 in diabetes). These
differences in GLUT4 localization could not be explained by
nonspecific or generalized effects on membrane subfractionation, as demonstrated in Table III. Recoveries of protein,
phospholemman, phospholamban, and the a-1 subunit of the
DHP (t-tubule marker) were similar among insulin sensitive,
insulin resistant, and type 2 diabetic subgroups in each sucrose
gradient fraction from both basal and insulin-stimulated muscle (P 5 NS).

Figure 3. Effects of insulin on GLUT4 in muscle membrane subfractions from insulin-sensitive, insulin-resistant, and type 2 diabetic subgroups. Muscle biopsies were obtained under
basal (closed bar) and insulin-stimulated (open
bar) conditions from insulin sensitive (IS) and
resistant (IR) subjects based on maximal glucose disposal rates . or , 15 mg/kg lean body
mass/min, respectively. Type 2 diabetics (DM)
were also studied. Non-equilibrium sucrose
density membrane subfractions were obtained,
and subjected to immunoblot analyses as described for Fig. 2. GLUT4 was quantified by
autoradiography and densitometry, and
mean6SE levels are shown in the 25% (left)
and 32% (right) sucrose density subfractions
corresponding to subgroups delineated in Table I (protocol 2).
Defective GLUT4 Trafficking and Translocation in Human Muscle
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Table III. Protocol 2: Percent Recovery of Protein and
Membrane Markers in Muscle Membrane Subfractions

Table IV. Effects of Insulin on the IRAP (vp165) in Muscle
Membrane Subfractions from Insulin-sensitive,
Insulin-resistant, and Type 2 Diabetic Subgroups

Sucrose gradient fraction
Sucrose gradient fraction
25%

Protein recovery*
Insulin-sensitive
Insulin-resistant
Type 2 diabetes
Phospholemman recovery*
Insulin-sensitive
Insulin-resistant
Type 2 diabetes
Phospholamban recovery*
Insulin-sensitive
Insulin-resistant
Type 2 diabetes
DHP*
Insulin-sensitive
Insulin-resistant
Type 2 diabetes

28%

32%

Pellet

4.960.8
4.460.7
3.960.7

3.461.2
2.760.3
2.260.3

2.260.5
2.660.4
2.661.0

4.661.0
5.761.0
4.861.0

2866
3069
2764

1264
1263
1463

863
1264
862

762
663
963

1062
1161
1264

1061
1164
1263

561
662
662

962
1064
963

1861
2161
1662

3163
3663
3063

1662
1663
1662

962
862
1061

*Data represent percent recovery in the membrane fractions of the total
present in postnuclear homogenates. Density gradient subfractions were
retrieved before equilibrium separation of membranes could occur (see
protocol 2). Data from basal and insulin-stimulated muscle were similar
and were combined to obtain the mean values.

GLUT4 vesicles also contain IRAP or vp165, which translocates together with GLUT4 to the cell surface (36, 37). To
further test for abnormalities in GLUT4 vesicle traffic, relative
amounts of IRAP were assessed in the muscle membrane subfractions by immunoblot analysis; the data are shown in Table
IV. The data generally demonstrate the same two abnormalities in insulin resistant subgroups that were observed for
GLUT4. First in basal muscle, 2.6–4.3 times more IRAP is localized in denser membrane vesicles recovered in the bottom
pellet of the gradient in both insulin-resistant and diabetic subgroups than in insulin-sensitive subjects. Second, in insulinsensitive subjects, insulin increased IRAP by 1.85-fold in the
28% sucrose fraction, whereas this effect was absent in both
insulin-resistant nondiabetic and diabetic subgroups. Thus,
similar to GLUT4, IRAP is redistributed to a denser membrane compartment and does not translocate in response to insulin in insulin resistant subjects. The discrepancy that insulin
augments GLUT4 in the 32% sucrose fraction and IRAP in
the 28% fraction in the insulin sensitive subgroup may be explained by the fact that not all cellular GLUT4 is located in
IRAP-containing vesicles (39, 40) and/or that different functional pools of intracellular GLUT4 vesicles contain variable
amounts of IRAP relative to GLUT4 (41).
The GLUT4 increment in the 32% fraction is a quantitative
marker for insulin sensitivity. To examine the relationship between GLUT4 changes in the 32% fraction (protocol 2) and
insulin sensitivity, we calculated the insulin-mediated increase
over basal in each individual subject. Mean data are shown in
Fig. 4. The GLUT4 increment in the insulin sensitive group
was 2.82-fold, which represents a 182% increase over basal values; this was approximately three times higher (P , 0.01) than
2382
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Insulin-sensitive
Basal
Insulin
Insulin-resistant
Basal
Insulin
Type 2 diabetics
Basal
Insulin

25%

28%

32%

Pellet

6.566
5.261.1

3.360.5
6.161.3*

3.461.1
3.961.3

3.861.2
3.860.7

3.360.9
3.660.7

4.460.8
4.661.1

4.061.0
4.861.0

9.761.2‡
10.266‡

3.260.8
3.960.8

4.560.4
4.460.7

5.260.6
4.760.4

16.361.3‡
17.863.2‡

Skeletal muscle biopsies were subjected to non-equilibrium sucrose
density membrane subfractionation (protocol 2), and subfractions were
subjected to immunoblot analysis using antibodies against IRAP. The
data represent the mean6SE of relative levels in the various subgroups.
*P , 0.05 when compared with value in basal muscle from insulin-sensitive subjects. ‡P , 0.05 when compared with values in the pellet from insulin-sensitive subjects.

the 54% increase in insulin-resistant subjects (1.54-fold) and
the 63% increase in Type 2 Diabetes (1.63-fold). Thus, the
ability of insulin to augment GLUT4 in the 32% fraction was
markedly impaired even in normoglycemic insulin-resistant individuals, and could not be attributed to antagonistic effects of
hyperglycemia on insulin action (4, 42) (for example, “glucose
toxicity”). To assess the relationship between the insulin effect
in the 32% fraction and glycemia-independent insulin resistance, the GLUT4 increment was correlated with the maximally stimulated glucose uptake rate in nondiabetic subjects
(for example, insulin-sensitive plus -resistant subjects). Fig. 5
shows that there was a positive and statistically significant correlation between these two variables. Two aspects of the data
indicate that the association between insulin resistance and
low GLUT4 increment was independent of obesity. First, BMI
was not correlated with GLUT4 increment (P 5 NS), and, second, the GLUT4 increment was found to be greater in insulin
sensitive than in insulin-resistant subjects (Fig. 4) despite the
fact that these subgroups were well matched for body mass index (Table I).

Discussion
In this study, sucrose density gradients were used to separate
membrane subfractions under two conditions, at equilibrium
and under non-equilibrium conditions after a shortened centrifugation time. Data using membrane fractions obtained under non-equilibrium conditions demonstrated that insulin augments GLUT4 by 2.8-fold in one sucrose gradient fraction
(32% sucrose), concomitant with a trend towards reduction in
other fractions (25% and 28% sucrose) in insulin-sensitive individuals. These observations support the conclusion that insulin stimulates glucose transport via translocation of GLUT4 to
sarcolemma in human muscle.
Investigators have relied on either subcellular membrane

Figure 4. Insulin-mediated increase in GLUT4 in the 32% sucrose
density membrane subfraction. The GLUT4 increment in the 32%
sucrose density membrane subfraction from insulin-stimulated muscle was calculated as fold increase over basal in each individual (see
Fig. 3). Data represent the mean6SE of increments in muscle from
insulin-sensitive (IS), insulin-resistant (IR), and type 2 diabetic (DM)
individuals. **P , 0.01 compared with IS.

fractionation or immunocytochemistry of basal and insulinstimulated muscle to resolve GLUT4 translocation. Subcellular fractionation of skeletal muscle has proven much more
difficult than it has in adipocytes; the effectiveness of this

biochemical approach in muscle has been limited by poor recovery of membrane markers, a high degree of contamination
among membrane subfractions, and lack of a marker that defines the intracellular pool. In rat muscle, several groups of
investigators have persevered and obtained generally concordant data showing that insulin leads to two- to threefold enrichment of transporters in a sarcolemma-enriched fraction
and a decrease in these parameters in microsomes (29, 43, 44).
Biochemical study of human muscle is more limited. In our experiments using membranes subfractionated to equilibrium,
insulin stimulation did not affect GLUT4 distribution in control or diabetic subjects, and translocation was not apparent,
suggesting that GLUT4 donor and acceptor membranes are
both present in the same fractions. Similarly, Lund et al. (45)
failed to demonstrate insulin-mediated GLUT4 translocation
in both non-diabetic controls and type 2 diabetic patients.
Guma et al. (46) were later able to show highly variable responses with a mean 60% GLUT4 increase in one sucrose density membrane subfraction together with 50% decrease in
another in muscle from normoglycemic individuals. The immunocytochemical approach has demonstrated recruitment of
intracellular GLUT4 to sarcolemma in both rats and humans
(4), although there has been controversy regarding the intracellular localization in basal muscle (for example, tubulovesicular structures, subsarcolemmal vesicles, transverse tubules
and terminal cisternae-triads). In humans, Friedman et al. (47)
used immunogold EM to show that insulin moved GLUT4
from tubulovesicular structures and triads to sarcolemma, and
Kelley et al. (6), using confocal laser scanning microscopy
found that insulin doubled GLUT4 label at sarcolemma. Thus,
despite some points of controversy and inconsistency, previous
data point to GLUT4 translocation as an important mechanism of transport stimulation in human muscle.
The current data also provide biochemical evidence that

Figure 5. The relationship between the
GLUT4 increase in the 32% sucrose density membrane fraction and insulin sensitivity. In muscle from individual normoglycemic subjects (IS and IR from Fig. 4), the
fold increase in GLUT4 (insulin-stimulated
over basal) in the 32% sucrose density
membrane subfraction was correlated with
the maximally stimulated in vivo glucose
disposal rate normalized per kilogram lean
body mass.
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impaired GLUT4 translocation in muscle can explain human
insulin resistance. Such a translocation defect has been inferred as a cause of human insulin resistance, without much
supportive empirical data, ever since muscle GLUT4 expression was found to be normal in these patients (17, 18). Insulin’s
ability to increase GLUT4 in the 32% sucrose fraction was significantly correlated with maximally-stimulated glucose disposal rates, an in vivo measure of insulin sensitivity that largely
reflects insulin action in muscle. Thus, the GLUT4 increase in
the 32% sucrose fraction either represents GLUT4 recruitment to sarcolemma or is a quantitative marker for this process. When the data were considered in the context of subject
subgroups, the insulin-mediated GLUT4 increment was markedly reduced in both insulin-resistant and type 2 diabetic individuals (z 1.5-fold above basal) when compared with the 2.8fold increase in insulin-sensitive subjects. These differences
were not accompanied by differences in organelle marker proteins in the various membrane subfractions, indicating that the
abnormalities were specific for GLUT4. The data demonstrate
a defect in insulin-mediated GLUT4 translocation that is
equally severe in insulin-resistant patients with and without diabetes. Recent reports indicate that more intracellular GLUT4
may translocate to t-tubule membranes than surface sarcolemma (48–50). The 32% sucrose fraction contains ample
quantities of the protein marker for t-tubules as well as phospholemman which is densely distributed along sarcolemma in
cardiac muscle (33, 34), but so do other fractions. The data imply that GLUT4 is recruited to a particular domain of sarcolemma that is enriched in the 32% sucrose fraction under these
conditions, and this step is impaired in insulin-resistant subjects.
The current biochemical results are consistent with recent
immunocytochemical data reported by Kelley et al. (6), who
showed reduced GLUT4 staining associated with sarcolemma
following insulin stimulation in obese and type 2 diabetic patients. However, our data indicate that the translocation defect
is not a function of obesity since insulin sensitive and resistant
subgroups were well-matched for body mass index and percent
body fat. Zierath et al. (19) observed a 1.6-fold GLUT4 increase in a plasma membrane fraction from nondiabetic controls but no effect of insulin in type 2 diabetics. The current
data, using non-equilibrium membrane subfractions, show a
much larger increment (2.8-fold) in insulin-sensitive nondiabetics. Analysis of the current data, together with those of
Kelley et al. (6) and Zierath et al. (19), illustrates an important
point when studying insulin resistance in nondiabetic and diabetic subjects. There are large individual differences in insulin
sensitivity among normoglycemic “controls,” and this variation is largely independent of measures of generalized obesity
(for example, both lean and obese subjects can be either very
insulin sensitive or resistant) (51–53). Therefore, nondiabetic
subjects should not be considered as a homogeneous group in
comparison with type 2 diabetic patients, and obesity cannot
effectively be used to identify which nondiabetic subjects are
insulin resistant. One explanation for the larger insulin effect
(2.8-fold GLUT4 increment in the insulin-sensitive subgroup)
is that we have defined a control group on the basis of insulin
sensitivity distinct from insulin-resistant nondiabetics. The
translocation defect in the current paper is pertinent to the
larger obesity-independent component of insulin resistance.
Furthermore, the study of separate insulin-sensitive, -resistant,
and diabetic subgroups can distinguish defects induced by hy2384
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perglycemia. The translocation defect associated with insulin
resistance cannot be attributed to effects of hyperglycemia or
“glucose toxicity” (4, 42), since it is equally severe in the normoglycemic insulin resistant and type 2 diabetic subgroups.
Thus, impaired translocation could contribute to insulin resistance in prediabetic individuals and contribute to the insulin
resistance syndrome (for example, syndrome X) (1). The relevance of the translocation defect to the pathogenesis of the insulin resistance syndrome is a hypothesis deserving further
study.
An additional important observation was that the translocation defect was accompanied by a second abnormality in
GLUT4 subcellular localization demonstrable even in basal
muscle. This novel abnormality was clearly observed after
equilibrium separation of sucrose density membrane subfractions but was also evident in the experiments using non-equilibrium subfractions. Greater amounts of GLUT4 were targeted to dense membrane vesicles (recovered in the 32%
sucrose fraction and bottom pellet), and lesser amounts recovered in lighter vesicles (recovered in 25 and 28% sucrose fractions), in insulin-resistant subgroups compared with insulinsensitive controls. This accumulation of GLUT4 in denser
membrane vesicles was specific for GLUT4 and did not affect
sarcolemma and sarcoplasmic reticulum membrane markers.
A similar pattern of abnormalities in insulin-resistant subjects
was observed for IRAP (or vp165), a constituent of GLUT4containing vesicles (36, 37). In basal muscle from both insulin
resistant nondiabetic and diabetic individuals, IRAP was redistributed to dense membrane vesicles recovered in the sucrose
gradient pellet relative to that observed in the insulin-sensitive
subgroup. In addition, insulin was able to augment IRAP in
the 28% sucrose fraction in the insulin-sensitive subjects but
had no effect in the insulin resistant subgroups. An important
difference in insulin-sensitive subjects was that insulin increased GLUT4 in the 32% fraction and IRAP in the 28%
fraction. The data do not explain the reason for this difference.
However, it is known that different functional pools of intracellular GLUT4 vesicles in rat skeletal muscle and other cells
contain variable proportions of IRAP relative to GLUT4 (39–
41). These observations provide possible explanations of why
translocation of IRAP and GLUT4 were resolved in different
sucrose density fractions. In general, the data are complementary. The important points are that GLUT4 and IRAP accumulated in or were targeted to a dense membrane compartment, and this abnormality was associated with a defect in
insulin-mediated translocation in insulin-resistant subjects.
This combination of defects in GLUT4 traffic and targeting
and translocation is analogous to a pattern we have previously
observed in human adipocytes. In insulin-resistant omental adipocytes from women with gestational diabetes mellitus, a
much greater proportion of cellular GLUT4 was localized in
dense membrane vesicles (cofractionating with plasma membranes and high-density microsomes) in basal cells compared
with that in nondiabetic gravidas, and there was little or no
GLUT4 recruitment from microsomes to plasma membrane in
response to insulin (16). In subcutaneous adipocytes from type
2 diabetic patients, it is difficult to accurately assess subcellular
trafficking due to the profound reduction in GLUT4 expression (15). More recently, we (54) have been able to localize
GLUT4 vesicles in membrane fractions via study of IRAP (36,
37). In adipocytes from normal controls, IRAP and GLUT4
were observed to translocate from low-density microsomes to

plasma membrane in response to insulin. In contrast, in diabetes, IRAP accumulated in vesicles cofractionating with plasma
membrane and high-density microsomes, and this was associated with impaired insulin-mediated translocation of IRAP.
Based on current and previous data, we propose that a defect
in GLUT4 trafficking and targeting causes human insulin resistance and is common to both skeletal muscle and adipocytes.
This defect leads to GLUT4 accumulation in a dense membrane compartment from which transporters are unable to be
recruited to cell surface membranes. This mechanism of insulin resistance is operative in adipocytes but is relegated to
secondary importance by a profound reduction in GLUT4
expression in type 2 diabetes. However, this mechanism predominates in skeletal muscle where normal expression of
GLUT4 is maintained.
In the current experiments, the non-equilibrium sucrose
density gradient fractions show a high degree of cross contamination for sarcolemma (phospholemman), sarcoplasmic reticulum (phospholamban), and t-tubule (a-1 subunit of the dihydropyridine binding complex) markers. Even though there is
extensive overlap of marker proteins, we have defined experimental conditions in human muscle showing that (i) under
basal conditions, GLUT4 accumulates or is redistributed to a
dense membrane compartment in insulin resistant individuals
compared with insulin sensitive subjects; and (ii) in response to
insulin, specific changes in GLUT4 localization are correlated
with glucose uptake activity and are impaired in insulin resistant subjects. The data constitute strong operational evidence
for combined defects in GLUT trafficking and translocation in
skeletal muscle as a cause for human insulin resistance.
The biochemical basis of defects in GLUT4 trafficking remains to be defined. A translocation defect per se could be due
to either impaired insulin signal transduction or lie intrinsic to
the glucose transporter effector system. Reduced insulin receptor tyrosine kinase activity, phosphorylation of insulin receptor substrate-1, and activation of PI-3-kinase have been
observed in skeletal muscle from obese and type 2 diabetic patients (20). While signal transduction abnormalities may be
contributory, it should be emphasized that the translocation
defect is associated with accumulation of GLUT4 in dense
membrane vesicles in basal tissue. Thus, the defect in cellular
targeting or trafficking of GLUT4 is independent of insulin.
The clear implication is that the abnormality in basal GLUT4
targeting and trafficking is a distinct defect intrinsic to the glucose transport system, which is then mechanistically linked to
impaired translocation. This is in contrast to other known cellular (55) and animal models (42, 56) of insulin resistance that
involve isolated translocation defects without evidence that
GLUT4 trafficking is disturbed under basal conditions. GLUT4
vesicle trafficking is constitutive, highly regulated, multicompartmental (4, 21), and involves multiple proteins that also direct exocytosis and endocytosis of synaptic neurosecretory vesicles (22–25). It is, therefore, feasible that defects at any of
several steps could alter trafficking and targeting of GLUT4 to
produce the novel pattern of abnormalities observed in human
skeletal muscle. It will be important to elucidate molecular
mechanisms leading to GLUT4 accumulation in denser membrane vesicles, the identity of this membrane compartment,
and how this alteration impairs translocation in response to insulin. These defects would have important implications for
both treatment and prevention of type 2 diabetes and the insulin resistance syndrome.
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